You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿联酋:国药集团新冠疫苗有效率为86%
阿思达克 12-09 14:34
阿联酋卫生部长表示,中国国药集团研发的新冠疫苗中期测试分析显示,该疫苗有效率为86%。分析亦显示该疫苗中和抗体血清阳转率为99%,对预防轻微至严重个案的有效率为100%。

阿联酋7月已在当地就该疫苗进行第三阶段临床测试,并於9月批准对特定人士作紧急使用,该国目前已批准该疫苗注册。

阿联酋的测试由国药集团旗下中国生物技术股份有限公司、阿布扎比人工智能及云计算公司Group 42(G42)及阿布扎比卫生部合作进行。

国药集团及G42亦在埃及、约旦及巴林合作进行新冠疫苗测试。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account